ArticleAnnals of clinical microbiology and antimicrobials2025
Synergistic effect of lactoferrin combined with fluconazole to overcome antifungal resistance in Candida species.
Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic Tools for Vulvovaginal Candidiasis: Current and Emerging Antifungal Agents.Journal of fungi (Basel, Switzerland) · 2026Review
- Iron acquisition mechanisms of human skin-associated fungi.FEMS yeast research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe incidence of drug-resistant candidiasis has increased in recent decades, leading to significant treatment challenges and high morbidity and mortality rates. The development of new therapeutic options is crucial, but it is a complex and time-consuming process; an interesting strategy to face this problem is to combine existing antifungal drugs with synergistic agents to enhance treatment efficacy, reduce dosage and prevent resistance development.
methodsWe analyzed the activity of lactoferrin against 80 isolates of 14 Candida species, including Candida auris according to both EUCAST and CLSI guidelines. Moreover, interaction between fluconazole and lactoferrin was assessed by checkerboard method against a selection of 38 isolates of eight Candida species, and by time-kill curves against six isolates of two Candida species, including fluconazole susceptible and resistant isolates.
resultsSynergistic and additive effects were demonstrated, with effective inhibition of Candida growth. Furthermore, combination therapy significantly reduced fluconazole minimum inhibitory concentrations (MICs) and showed synergistic effect against fluconazole-resistant isolates.
conclusionsLactoferrin has significant potential value in the treatment of candidiasis and further exploration of its potential clinical applications is of great importance. The ability of lactoferrin to enhance the efficacy of existing antifungal drugs while potentially reducing the development of antifungal resistance makes it an intriguing candidate for future research and development efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.